A brain-computer interface startup co-founded by a former Neuralink executive just secured $230 million in new funding — and it may be closer to putting a product in patients' hands than anyone in the industry. Science Corporation, led by Max Hodak, is betting that a rice-grain-sized eye implant will make it the first BCI company to actually reach the market. Here's what you need to know.
 |
| Credit: Science Corp. |
The $230 Million Bet on Brain-Computer Interface Technology
Science Corporation announced Wednesday that it has closed a $230 million Series C funding round. According to a source close to the company, the round values Science Corp. at $1.5 billion post-money — a striking figure for a startup operating in one of biotech's most complex and competitive spaces.
The brain-computer interface sector has long been viewed as a moonshot territory, drawing headlines but few concrete clinical results. While the broader venture capital world has spent the last two years chasing artificial intelligence deals, Science Corp. has quietly been running clinical trials, refining hardware, and navigating regulatory pathways. That focused execution appears to be resonating with investors in a big way.
The funding gives the company the financial runway to push toward what it calls a historic milestone: becoming the first BCI company to commercially launch a product. If its timeline holds, that moment could arrive as soon as mid-2026.
Who Is Behind Science Corp. — and Why It Matters
Max Hodak is not a newcomer to this space. He co-founded and served as president of Neuralink, the high-profile brain interface company, before departing in 2021 to start Science Corporation. That background gives him rare, deep insight into both the promise and the practical obstacles of developing implantable neural technology.
Hodak's departure from Neuralink and the founding of Science Corp. went largely under the radar at first. But the company has steadily built credibility through clinical results rather than press releases. The company's vision-restoration device recently landed on the cover of a major international news magazine — a signal that its work is being taken seriously far beyond the biotech investment community.
Having a founder with hands-on experience at the world's most famous BCI company is a meaningful differentiator. It means Science Corp. isn't starting from first principles. It's applying hard-won knowledge to a more targeted, near-term problem.
PRIMA: The Tiny Chip That Could Restore Vision for Millions
The company's flagship product is called PRIMA — a subretinal implant described as smaller than a grain of rice. When placed beneath the retina and paired with specially designed camera-equipped glasses, PRIMA is designed to restore functional vision in people suffering from advanced age-related macular degeneration.
Age-related macular degeneration, or AMD, is one of the leading causes of blindness in adults over 50, affecting millions of people worldwide. In its advanced stages, AMD destroys the central vision needed for reading, recognizing faces, and performing basic daily tasks. Current treatments can slow progression but cannot reverse vision loss once it has occurred. PRIMA is designed to change that.
The technology behind PRIMA wasn't developed entirely in-house. Science Corp. acquired the assets of a French medical device company called Pixium Vision in 2024, which had already begun early-stage trials. Science Corp. then refined the technology and completed the clinical work — and importantly, all clinical results being reported now are Science Corp.'s own.
The Clinical Results That Have the Medical World Paying Attention
The numbers coming out of Science Corp.'s trials are genuinely striking. Across 47 patients enrolled in trials spanning both Europe and the United States, 80% of participants showed meaningful improvement in visual acuity. More remarkably, those patients were able to read letters, numbers, and words — something that had not been clinically demonstrated before in this patient population.
Hodak described the significance of these outcomes in clear terms: to his knowledge, this is the first time that restoration of the ability to fluently read has ever been definitively shown in blind patients. That's not a modest claim — it's a potential landmark moment in the history of vision medicine.
Reading is a gateway skill. For patients who have lost central vision, the ability to read a prescription bottle, a text message, or a loved one's birthday card is transformative. It represents not just a medical outcome, but a restoration of independence and dignity. That human dimension is what sets PRIMA apart from previous attempts at vision restoration technology.
The Road to Market: Regulatory Timeline and What Comes Next
Science Corp. is not waiting for U.S. regulatory approval to begin reaching patients. The company has submitted a CE mark application to the European Union — the certification needed to sell medical devices commercially across EU member states. It expects to receive that approval in mid-2026.
If that approval comes through on schedule, Science Corp. plans to launch PRIMA in Europe immediately. This would make it the first brain-computer interface company to have a commercially available product anywhere in the world — a milestone the entire industry has been chasing for years without success.
The U.S. regulatory path through the Food and Drug Administration is likely to take longer, as it typically does for novel implantable devices. But a European launch would serve multiple purposes: it would generate real-world clinical data, build a commercial infrastructure, and establish proof of concept at scale before tackling the American market.
For patients in Europe living with advanced macular degeneration, this timeline carries enormous personal significance. The gap between a promising clinical trial and an approved commercial product is often measured in years or even decades. Mid-2026 is, by any measure, right around the corner.
Why This Moment Is Different From Past BCI Hype Cycles
Brain-computer interface technology has been generating buzz for years. Companies have announced bold timelines, published splashy presentations, and raised significant capital — only to find that the gap between prototype and patient is far wider than anticipated. The history of the field is littered with delays, pivots, and quiet wind-downs.
Science Corp.'s approach is different in a few important ways. Rather than pursuing a maximally ambitious full-brain interface from the start, the company focused on a specific, well-defined clinical problem: restoring central vision in people with advanced AMD. That focus sharpens the regulatory pathway, reduces the technical unknowns, and makes it easier to demonstrate clear patient benefit.
The decision to acquire and build on existing technology rather than starting from scratch also reflects a more mature operating philosophy. Science Corp. didn't need to prove the basic scientific concept — it needed to refine it, run rigorous trials, and navigate regulatory requirements. That is a fundamentally different and faster path to market than pure greenfield development.
With $230 million in fresh capital, a credible founding team, strong clinical data, and a defined regulatory timeline, Science Corp. looks less like a moonshot and more like a company on the verge of delivering something real.
What a Successful Launch Would Mean for the Broader BCI Industry
If Science Corp. becomes the first brain-computer interface company to bring a product to market, it will do more than help blind patients see again. It will serve as proof that the BCI sector can cross the finish line — something that would likely unlock a new wave of investment, regulatory confidence, and scientific collaboration across the entire field.
Other companies working on neural interfaces for paralysis, epilepsy, depression, and other conditions are watching closely. A successful commercial launch by Science Corp. would validate the entire category in the eyes of regulators, payers, and the medical establishment. It would also create a competitive pressure that could accelerate timelines across the industry.
For patients, researchers, and investors alike, mid-2026 may mark the beginning of a genuinely new era in medicine — one where the boundary between the brain and the outside world starts to dissolve in clinically meaningful, commercially available ways. Science Corp. is making a serious run at being the company that opens that door.
Comments
Post a Comment